Enhanced efficacy benzisoxazole derivative dosage forms and methods
OwnerMichelle Kramer, Peter Briscoe +2inventors
InventorsMichelle Kramer, Peter Briscoe, Sandra Boom, An Vermeulen
Life of this patent
Estimating the term…
Abstract
Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that provide enhanced efficacy when used in the treatment of schizophrenia and/or bipolar mania.
Claims63
A method of treating schizophrenia comprising:
- orally sustainably delivering an enhanced efficacious amount of a benzisoxazole derivative from an oral sustained release dosage form to a patient in need of treatment for schizophrenia;
- wherein the enhanced efficacious amount of a benzisoxazole derivative ranges from 2 mg to 18 mg.
A method of treating schizophrenia comprising:
- orally delivering a benzisoxazole derivative in an amount ranging from 2 mg to about 5 mg from an oral sustained release dosage form to a patient in need of treatment for schizophrenia.
A method of treating schizophrenia comprising:
- orally sustainably releasably delivering a benzisoxazole derivative to a patient in an amount effective to treat schizophrenia, wherein the amount effective to treat schizophrenia ranges from 2 mg to 18 mg.
A method of treating schizophrenia comprising:
- orally delivering a benzisoxazole derivative from an oral sustained release dosage form to a patient in an amount effective to treat schizophrenia, wherein the amount effective to treat schizophrenia ranges from 2 mg to 18 mg.
A method of treating bipolar mania comprising:
- orally sustainably delivering an enhanced efficacious amount of a benzisoxazole derivative from an oral sustained release dosage form to a patient in need of treatment for bipolar mania;
- wherein the enhanced efficacious amount of a benzisoxazole derivative ranges from 2 mg to 18 mg.
A method of treating bipolar mania comprising:
- orally delivering a benzisoxazole derivative in an amount ranging from 2 mg to about 5 mg from an oral sustained release dosage form to a patient in need of treatment for bipolar mania.
A method of treating bipolar mania comprising:
- orally sustainably releasably delivering a benzisoxazole derivative to a patient in an amount effective to treat bipolar mania, wherein the amount effective to treat bipolar mania ranges from 2 mg to 18 mg.
A method of treating bipolar mania comprising:
- orally delivering a benzisoxazole derivative from an oral sustained release dosage form to a patient in an amount effective to treat bipolar mania, wherein the amount effective to treat bipolar mania ranges from 2 mg to 18 mg.
A method of treating schizophrenia or bipolar mania comprising:
- orally sustainably delivering an enhanced efficacious amount of a benzisoxazole derivative from an oral sustained release dosage form to a patient in need of treatment for schizophrenia or bipolar mania;
- wherein the enhanced efficacious amount of a benzisoxazole derivative ranges from 2 mg to 18 mg.
A method of treating schizophrenia or bipolar mania comprising:
- orally delivering a benzisoxazole derivative in an amount ranging from 2 mg to about 5 mg from an oral sustained release dosage form to a patient in need of treatment for schizophrenia or bipolar mania.
A method of treating schizophrenia or bipolar mania comprising:
- orally sustainably releasably delivering a benzisoxazole derivative to a patient in an amount effective to treat schizophrenia or bipolar mania, wherein the amount effective to treat schizophrenia or bipolar mania ranges from 2 mg to 18 mg.
A method of treating schizophrenia or bipolar mania comprising:
- orally delivering a benzisoxazole derivative from an oral sustained release dosage form to a patient in an amount effective to treat schizophrenia or bipolar mania, wherein the amount effective to treat schizophrenia or bipolar mania ranges from 2 mg to 18 mg.
Dependencies are inferred from the claim text.